Updates are available Correction dated 2020-05-12
Click to view Correction: https://doi.org/10.1007/s00415-020-09855-8
Updates are available Correction dated 2021-06-25
Click to view Correction: https://doi.org/10.1007/s00415-021-10634-2
-
Authors
Bien, Christian G. http://orcid.org/0000-0003-2225-8654
Bien, Corinna I.
Dogan Onugoren, Müjgan
De Simoni, Desiree http://orcid.org/0000-0003-3705-8903
Eigler, Verena
Haensch, Carl-Albrecht http://orcid.org/0000-0001-6479-0265
Holtkamp, Martin
Ismail, Fatme S. http://orcid.org/0000-0003-3930-8056
Kurthen, Martin
Melzer, Nico
Mayer, Kristina
von Podewils, Felix http://orcid.org/0000-0002-3134-8697
Rauschka, Helmut
Rossetti, Andrea O. http://orcid.org/0000-0002-7878-172X
Schäbitz, Wolf-Rüdiger
Simova, Olga
Witt, Karsten
Höftberger, Romana http://orcid.org/0000-0002-5769-1100
May, Theodor W. http://orcid.org/0000-0001-6517-9425
- License Information
-
More Information
Article History
Received: 13 February 2020
Revised: 28 March 2020
Accepted: 28 March 2020
First Online: 3 April 2020
Change Date: 25 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-021-10634-2
Change Date: 12 May 2020
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-020-09855-8
Compliance with ethical standards
:
: Dr. CG Bien obtained honoraria for speaking engagements from UCB, Desitin (Hamburg, Germany), and Euroimmun. He receives research support from Deutsche Forschungsgemeinschaft (German Research Council, Bonn, Germany) and Gerd-Altenhof-Stiftung (Deutsches Stiftungszentrum, Essen, Germany). Dr. M Holtkamp obtained speaker’s honoraria and/or consultancy fees from Arvelle, Bial, Desitin, Eisai, GW Pharmaceuticals, Novartis, and UCB. Dr. N Melzer has received honoraria for lecturing and travel expenses for attending meetings from Biogen Idec, GlaxoSmith Kline, Teva, Novartis Pharma, Bayer Healthcare, Genzyme, Alexion Pharmaceuticals, Fresenius Medical Care, Diamed, and BIAL, and has received financial research support from Euroimmun, Fresenius Medical Care, Diamed, Alexion Pharmaceuticals, and Novartis Pharma. Dr. F von Podewils obtained honoraria for speaking engagements from UCB, Eisai, and BIAL. Dr H Rauschka obtained honoraria for speaking engagements, consulting, serving on advisory boards and funding for conference travels from Biogen, Merck, Novartis, Roche, Sanofi and Teva-Ratiopharm. Dr. R Höftberger obtained honoraria for speaking engagements from Euroimmun and Novartis. She receives research support from the Jubiläumsfonds der Österreichischen Nationalbank, Project 16919, and the GBS/CIDP Foundation International. The Medical University of Vienna receives payments for antibody assays. The other authors report no conflicts of interest.
: The study was approved by the Ethics committee of the University of Münster, Germany (2017–005-f-S).
: Not applicable (retrospective evaluation, waived by Ethics committee).
: Not applicable (retrospective evaluation, waived by Ethics committee).
: Any data not published within this article are available at the Epilepsy Center Bethel. Data will be shared upon request from any qualified investigator, maintaining anonymization of the patients.
: Not applicable.
